Cytodyn Stock Performance
| CYDY Stock | USD 0.11 0.01 8.33% |
The firm shows a Beta (market volatility) of 2.76, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cytodyn will likely underperform. At this point, Cytodyn has a negative expected return of -0.49%. Please make sure to confirm Cytodyn's treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Cytodyn performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Cytodyn has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's fundamental indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 33.9 M |
Cytodyn |
Cytodyn Relative Risk vs. Return Landscape
If you would invest 16.00 in Cytodyn on September 3, 2024 and sell it today you would lose (5.00) from holding Cytodyn or give up 31.25% of portfolio value over 90 days. Cytodyn is currently does not generate positive expected returns and assumes 4.3934% risk (volatility on return distribution) over the 90 days horizon. In different words, 39% of otc stocks are less volatile than Cytodyn, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cytodyn Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cytodyn's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Cytodyn, and traders can use it to determine the average amount a Cytodyn's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1112
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CYDY |
Estimated Market Risk
| 4.39 actual daily | 39 61% of assets are more volatile |
Expected Return
| -0.49 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Cytodyn is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cytodyn by adding Cytodyn to a well-diversified portfolio.
Cytodyn Fundamentals Growth
Cytodyn OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Cytodyn, and Cytodyn fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cytodyn OTC Stock performance.
| Return On Asset | -1.48 | |||
| Current Valuation | 286.7 M | |||
| Shares Outstanding | 832.97 M | |||
| Price To Earning | (3.14) X | |||
| Price To Book | 1,066 X | |||
| Price To Sales | 1,174 X | |||
| Revenue | 266 K | |||
| EBITDA | (157.59 M) | |||
| Cash And Equivalents | 4.68 M | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 37.35 M | |||
| Book Value Per Share | (0.14) X | |||
| Cash Flow From Operations | (77.72 M) | |||
| Earnings Per Share | (0.23) X | |||
| Total Asset | 29.18 M | |||
| Retained Earnings | (211.86 M) | |||
| Current Asset | 136.91 K | |||
| Current Liabilities | 508.07 K | |||
About Cytodyn Performance
Evaluating Cytodyn's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Cytodyn has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cytodyn has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
CytoDyn Inc. operates as a clinical-stage biotechnology company. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington. Cytodyn operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 23 people.Things to note about Cytodyn performance evaluation
Checking the ongoing alerts about Cytodyn for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Cytodyn help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cytodyn generated a negative expected return over the last 90 days | |
| Cytodyn has some characteristics of a very speculative penny stock | |
| Cytodyn has high historical volatility and very poor performance | |
| Cytodyn has a very high chance of going through financial distress in the upcoming years | |
| Cytodyn currently holds 37.35 M in liabilities. Cytodyn has a current ratio of 0.08, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Cytodyn until it has trouble settling it off, either with new capital or with free cash flow. So, Cytodyn's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cytodyn sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cytodyn to invest in growth at high rates of return. When we think about Cytodyn's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 266 K. Net Loss for the year was (210.82 M) with loss before overhead, payroll, taxes, and interest of (73.28 M). | |
| Cytodyn currently holds about 4.68 M in cash with (77.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. |
- Analyzing Cytodyn's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cytodyn's stock is overvalued or undervalued compared to its peers.
- Examining Cytodyn's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cytodyn's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cytodyn's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Cytodyn's otc stock. These opinions can provide insight into Cytodyn's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Cytodyn OTC Stock Analysis
When running Cytodyn's price analysis, check to measure Cytodyn's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytodyn is operating at the current time. Most of Cytodyn's value examination focuses on studying past and present price action to predict the probability of Cytodyn's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cytodyn's price. Additionally, you may evaluate how the addition of Cytodyn to your portfolios can decrease your overall portfolio volatility.